Mackenzie Financial Corp Sells 1,226 Shares of DaVita Inc. (NYSE:DVA)

Mackenzie Financial Corp reduced its holdings in shares of DaVita Inc. (NYSE:DVA) by 26.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,444 shares of the company’s stock after selling 1,226 shares during the quarter. Mackenzie Financial Corp’s holdings in DaVita were worth $477,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DVA. The Manufacturers Life Insurance Company grew its position in DaVita by 0.3% in the second quarter. The Manufacturers Life Insurance Company now owns 45,244 shares of the company’s stock valued at $6,269,000 after purchasing an additional 150 shares in the last quarter. Maverick Capital Ltd. grew its holdings in shares of DaVita by 168.4% in the 2nd quarter. Maverick Capital Ltd. now owns 11,553 shares of the company’s stock valued at $1,601,000 after acquiring an additional 7,248 shares in the last quarter. MBB Public Markets I LLC acquired a new stake in shares of DaVita in the second quarter valued at about $582,000. AXA S.A. raised its holdings in DaVita by 66.8% during the second quarter. AXA S.A. now owns 26,268 shares of the company’s stock worth $3,640,000 after acquiring an additional 10,521 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. boosted its position in DaVita by 60.2% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,498 shares of the company’s stock valued at $208,000 after purchasing an additional 563 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of analyst reports. TD Cowen upped their price objective on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Truist Financial increased their price target on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. UBS Group lifted their price objective on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Finally, Bank of America boosted their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $157.00.

DaVita Price Performance

Shares of DVA opened at $160.69 on Friday. The company’s 50-day moving average is $152.14 and its 200-day moving average is $142.92. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. The firm has a market capitalization of $14.09 billion, a PE ratio of 18.26, a PEG ratio of 0.91 and a beta of 0.87. DaVita Inc. has a fifty-two week low of $71.51 and a fifty-two week high of $166.04.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.15 billion. During the same period in the prior year, the firm earned $2.08 EPS. The business’s revenue was up 6.2% on a year-over-year basis. Equities analysts forecast that DaVita Inc. will post 9.99 EPS for the current year.

Insider Buying and Selling

In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at $36,299,008.35. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares of the company’s stock, valued at $36,299,008.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the transaction, the chief executive officer now directly owns 905,659 shares in the company, valued at $141,219,407.87. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 173,482 shares of company stock valued at $27,387,069. Insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.